FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Atadja

Research Profile

Chemicals & Drugs

Anatomy

Phenomena

Living Beings

Mouse

Physiology

Procedures

Co-author Network

Publications

TOP 3
Yonghua Yang; Bao Yong; Peter Atadja; Warren Fiskus; Tej K Pandita; Yoshinori Takahashi; Hong-Gang Wang; Kapil N Bhalla
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy.
Anna Scuto; Mark Kirschbaum; M Kujawski; Peter Atadja; R Buettner; J M Cermak; Richard Jove
SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
Wei Qi; Lin Teng; Xiaoxia Yan; Teddy Yang; Zhengtian Yu; Jue Zeng; Ji-Hu Zhang; Man Zhang; Ruipeng Zhang; Kehao Zhao; Tao Zhou; Ophelia Ardayfio; Peter Atadja; HoMan Chan; Zijun Chen; Shannon Chuai; Hong Fan; Jialuo Fang; Grace Feng; Justin Gu; Guobin Li; Ling Li; Min Li; Ying Lin; Xianghui Liu; Chris X Lu; Yuan Mi; En Li
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Atadja (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Yonghua Yang; Bao Yong; Peter Atadja; Warren Fiskus; Tej K Pandita; Yoshinori Takahashi; Hong-Gang Wang; Kapil N Bhalla
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(17):6841-6.
2013: Anna Scuto; Mark Kirschbaum; M Kujawski; Peter Atadja; R Buettner; J M Cermak; Richard Jove
SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
Cell death & disease 2013;4():e635.
2012: Wei Qi; Lin Teng; Xiaoxia Yan; Teddy Yang; Zhengtian Yu; Jue Zeng; Ji-Hu Zhang; Man Zhang; Ruipeng Zhang; Kehao Zhao; Tao Zhou; Ophelia Ardayfio; Peter Atadja; HoMan Chan; Zijun Chen; Shannon Chuai; Hong Fan; Jialuo Fang; Grace Feng; Justin Gu; Guobin Li; Ling Li; Min Li; Ying Lin; Xianghui Liu; Chris X Lu; Yuan Mi; En Li
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(52):21360-5.
2012: Warren C Fiskus; Siddhartha Ganguly; Stacey L Hembruff; Victor E Marquez; Uma Mudunuru; Rekha Rao; Jacqueline E Smith; Eduardo Sotomayor; Jianguo Tao; Peter Atadja; Ramesh Balusu; Kapil Bhalla
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6227-38.
2012: Sreedhar Venkannagari; Peter Atadja; Warren C Fiskus; Manuel Hidalgo; Anirban Maitra; Karissa Peth; Kapil N Bhalla
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Oncotarget 2012;3(11):1416-27.
2012: Andreas Fredenhagen; Matthias Kittelmann; Anton Kuhn; Jürgen Kühnöl; Lukas Oberer; Reiner Aichholz; Peter Atadja; Thierry Délémonté; Ping Wang; Michael D Shultz
Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Drug metabolism and disposition: the biological fate of chemicals 2012;40(5):1041-50.
2012: Miguel Lemaire; Eline Menu; Anders Österborg; Ben Van Camp; Els Van Valckenborgh; Prasoon Agarwal; Peter Atadja; Magnus Axelson; Elke De Bruyne; Charlotte Fristedt; Helena Jernberg-Wiklund; Olle Larsson; Karin Vanderkerken
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2230-9.
2012: Rekha Rao Manepalli; Jacqueline E Smith; Sreedhar Venkannagari; Peter Atadja; Ramesh Balusu; Lata Chauhan; Warren C Fiskus; Kyungsoo Ha; Stacey L Hembruff; Uma Mudunuru; Kapil N Bhalla
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Molecular cancer therapeutics 2012;11(4):973-83.
2012: Ying Lin; Chris Lu; Peter Meier; Clemens Scheufler; Zhaofu Wang; Yao-Chang Xu; Kehao Zhao; Shaolian Zhou; Peter Atadja; Hong Fan; Mathias Frederiksen; Jun Gao; Weihui Guo; Edmund Harrington; Lei Jiang; En Li; Shu Li; X Justin Gu
Detecting S-adenosyl-L-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay.
Analytical biochemistry 2012;423(1):171-7.
2012: Satbir Thakur; Peter Atadja; Xiaolan Feng; Amudha Ganapathy; Manoj Kumar Mishra; Don Morris; Zhong Qiao Shi; Karl Riabowol
ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.
PloS one 2012;7(8):e43671.
2012: Solomon Nwaka; Barthelemy Nyasse; Alexander Ochem; Blessed Okole; Ole Olesen; Bernadette Ramirez; Robert Ridley; Issa Sanou; Ivan Adae-Mensah; Peter Atadja; Dominique Besson; Sanaa Botros; Foluke Fakorede; Anastasia Guantai; Uford Inyang; Victor Konde; Glaudina Loots; Charles Mgone; Peter Ndumbe; Tshinko Ilunga
Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent.
BMC international health and human rights 2012;12():11.
2011: Li Wang; Hailong Zhang; Shaolian Zhou; Jidong Zhu; Peter Atadja; Jingquan Dai; Justin Gu; En Li; Ling Li; Chris Lu; Xiao Luo; Kehao Zhao
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
The Journal of biological chemistry 2011;286(44):38725-37.
2011: Michael Shultz; Joghee Raju Suresh; Laszlo Urban; Ping Wang; Lewis Whitehead; Yan Yan-Neale; Haiyan Zhang; Liping Zhou; Sheri Bickford; Kristen Buteau; Xueying Cao; Christine Chen; Young Shin Cho; Nicole Davis; Jianmei Fan; Mats Holmqvist; Meier Hsu; Lei Jiang; Gang Liu; Qiang Lu; Chetan Patel; Mannangatti Selvaraj; Peter Atadja
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Bioorganic & medicinal chemistry letters 2011;21(16):4909-12.
2011: Lewis Whitehead; Yanyi Zhu; Ritesh Tichkule; Ruben A Tommasi; Brian Vash; Ping Wang; Peter Atadja; Tavina Claiborne; Markus R Dobler; Jonathan E Grob; Andrew McRiner; Margaret R Pancost; Anup Patnaik; Branko Radetich; Wenlin Shao; Michael Shultz; Travis Stams
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
Bioorganic & medicinal chemistry 2011;19(15):4626-34.
2011: Ben P Martin; Ailsa J Frew; Michael Bots; Stephen Fox; Fenella Long; Kazuyoshi Takeda; Hideo Yagita; Peter Atadja; Mark J Smyth; Ricky Johnstone
Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
International journal of cancer. Journal international du cancer 2011;128(11):2735-47.
2011: Piergiorgio Pettazzoni; Stefania Pizzimenti; Cristina Toaldo; Paula Sotomayor; Luigina Tagliavacca; Song Liu; Dan Wang; Rosalba Minelli; Leigh Ellis; Peter Atadja; Eric Ciamporcero; Mario Umberto Dianzani; Giuseppina Barrera; Roberto Pili
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Free radical biology & medicine 2011;50(2):313-22.
2011: Shijun Fu; Hua Jiang; Lei Jiang; En Li; Chris Lu; Song Shi; Peter Atadja; Shannon Chuai; Qi Fei; Wen Xiong; Jianyong Shou
Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profiling.
PloS one 2011;6(11):e27965.
2011: Leigh Ellis; Kristin Lehet; Song Liu; Kiersten M Miles; Remi Adelaiye; Peter Atadja; Michael A Carducci; Swathi Ramakrishnan; Dan Wang; Roberto Pili
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
PloS one 2011;6(11):e27178.
2010: Aditya Mandawat; Warren C Fiskus; Kathleen M Buckley; Kelly Robbins; Rekha Rao Manepalli; Ramesh Balusu; Jean-Marc Navenot; Zixuan Wang; celalettin ustun; Daniel G Chong; Peter Atadja; Nobutaka Fujii; Stephen Peiper; Kapil N Bhalla
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
Blood 2010;116(24):5306-15.
2010: Wenlin Shao; Joseph D Growney; Yun Feng; Gregory O'Connor; Minying Pu; Wenjing Zhu; Yung-Mae Yao; Paul Kwon; Stephen Fawell; Peter Atadja
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
International journal of cancer. Journal international du cancer 2010;127(9):2199-208.
2010: Rekha Rao Manepalli; Srilatha Nalluri; Warren C Fiskus; Andrew Savoie; Kathleen M Buckley; Kyungsoo Ha; Ramesh Balusu; Atul D Joshi; Veena Coothankandaswamy; Jianguo Tao; Eduardo Sotomayor; Peter Atadja; Kapil N Bhalla
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4742-54.
2010: Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San Miguel
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Haematologica 2010;95(5):794-803.
2010: Young Shin Cho; Lewis Whitehead; Jianke Li; Christine H-T Chen; Lei Jiang; Markus Vögtle; Eric Francotte; Paul Richert; Trixie Wagner; Martin Traebert; Qiang Lu; Xueying Cao; Berengere Dumotier; Jasna Fejzo; Srinivasan Rajan; Ping Wang; Yan Yan-Neale; Wenlin Shao; Peter Atadja; Michael Shultz
Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
Journal of medicinal chemistry 2010;53(7):2952-63.
2010: Rekha Rao Manepalli; Srilatha Nalluri; Ravindra Kolhe; Yonghua Yang; Warren C Fiskus; Jianguang Chen; Kyungsoo Ha; Kathleen M Buckley; Ramesh Balusu; Veena Coothankandaswamy; Atul D Joshi; Peter Atadja; Kapil N Bhalla
Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells.
Molecular cancer therapeutics 2010;9(4):942-52.
2010: Martin Kaiser; Britta Lamottke; Maren Mieth; Michael Rugaard Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Peter Atadja; Ulrike Heider; Ivana von Metzler; Seval Türkmen; Orhan Sezer
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
European journal of haematology 2010;84(4):337-44.
2010: Roberto R Rosato; Sarah S Kolla; Stefanie K Hock; Jorge A Almenara; Ankita Patel; Sanjay Amin; Peter Atadja; Paul B Fisher; Paul Dent; Steven Grant
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.
The Journal of biological chemistry 2010;285(13):10064-77.
2010: Elke De Bruyne; Tomas Bos; Frans Schuit; Els Van Valckenborgh; Eline Menu; Lieven Thorrez; Peter Atadja; Helena Jernberg-Wiklund; Karin Vanderkerken
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
Blood 2010;115(12):2430-40.
2010: Antonia Kalushkova; Mårten Fryknäs; Miguel Lemaire; Charlotte Fristedt; Prasoon Agarwal; Maria Eriksson; Sarah Deleu; Peter Atadja; Anders Osterborg; Kenneth Nilsson; Karin Vanderkerken; Fredrik Oberg; Helena Jernberg-Wiklund
Polycomb target genes are silenced in multiple myeloma.
PloS one 2010;5(7):e11483.
2009: Yongchao Wang; Warren C Fiskus; Daniel G Chong; Kathleen M Buckley; Kavita Natarjan; Rekha Rao Manepalli; Atul D Joshi; Ramesh Balusu; Sanjay Koul; Jianguang Chen; Andrew Savoie; celalettin ustun; Anand P Jillella; Peter Atadja; Ross Levine; Kapil N Bhalla
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
Blood 2009;114(24):5024-33.
2009: Patricia Maiso; Enrique Colado; Enrique M Ocio; Mercedes Garayoa; J Martín; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
Leukemia 2009;23(12):2265-74.
2009: Warren C Fiskus; Yongchao Wang; Arun Sreekumar; Kathleen M Buckley; Huidong Shi; Anand P Jillella; celalettin ustun; Rekha Rao Manepalli; Pravina Fernandez; Jianguang Chen; Ramesh Balusu; Sanjay Koul; Peter Atadja; Victor E Marquez; Kapil N Bhalla
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Blood 2009;114(13):2733-43.
2009: Peter Atadja
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Cancer letters 2009;280(2):233-41.
2009: Michael B Prystowsky; Alfred Adomako; Richard V Smith; Nicole Kawachi; Wendy McKimpson; Peter Atadja; Quan Chen; Nicolas F Schlecht; Joanna L Parish; Geoffrey Childs; Thomas J Belbin
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The Journal of pathology 2009;218(4):467-77.
2009: Leigh Ellis; Michael Bots; Ralph K Lindemann; Jessica E Bolden; Andrea Newbold; Leonie A Cluse; Clare L Scott; Andreas Strasser; Peter Atadja; Scott W Lowe; Ricky Johnstone
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Blood 2009;114(2):380-93.
2009: In Ah Kim; Mina No; Jang-Mi Lee; Jin Hee Shin; Jee Sun Oh; Eun Jung Choi; Il Han Kim; Peter Atadja; Eric J Bernhard
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(1):125-32.
2009: Giuseppe Floris; Maria Debiec-Rychter; Raf Sciot; Cristiana Stefan; Steffen Fieuws; Kathleen Machiels; Peter Atadja; Agnieszka Wozniak; Gavino Faa; Patrick Schöffski
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4066-76.
2009: Leigh Ellis; Peter Atadja; Ricky Johnstone
Epigenetics in cancer: targeting chromatin modifications.
Molecular cancer therapeutics 2009;8(6):1409-20.
2009: Warren C Fiskus; Kate Buckley; Rekha Rao Manepalli; Aditya Mandawat; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul D Joshi; Sunil Upadhyay; Peter Atadja; Kapil N Bhalla
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
Cancer biology & therapy 2009;8(10):939-50.
2009: Jianguang Chen; Warren C Fiskus; Kelly Eaton; Pravina Fernandez; Yongchao Wang; Rekha Rao Manepalli; Pearl Lee; Rajeshree Joshi; Yonghua Yang; Ravindra Kolhe; Ramesh Balusu; Prasanthi Chappa; Kavita Natarjan; Anand P Jillella; Peter Atadja; Kapil N Bhalla
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Blood 2009;113(17):4038-48.
2009: James Symanowski; Nicholas Vogelzang; Leigh Zawel; Peter Atadja; Harvey I Pass; Sunil Sharma
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(2):149-60.
2008: Johann S de Bono; Rebecca Kristeleit; Anthony Tolcher; Peter Fong; Simon Pacey; Vasilios Karavasilis; Monica Mita; Heather Shaw; Paul Workman; Stan Kaye; Eric K Rowinsky; Wynne Aherne; Peter Atadja; Jeffrey W Scott; Amita Patnaik
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6663-73.
2008: Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Molecular cancer therapeutics 2008;7(10):3285-97.
2008: Warren C Fiskus; Rekha Rao Manepalli; Pravina Fernandez; Bryan Herger; Yonghua Yang; Jianguang Chen; Ravindra Kolhe; Aditya Mandawat; Yongchao Wang; Rajeshree Joshi; Kelly Eaton; Pearl Lee; Peter Atadja; Stephen Peiper; Kapil N Bhalla
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Blood 2008;112(7):2896-905.
2008: Rekha Rao Manepalli; Warren C Fiskus; Yonghua Yang; Pearl Lee; Rajeshree Joshi; Pravina Fernandez; Aditya Mandawat; Peter Atadja; James E Bradner; Kapil N Bhalla
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Blood 2008;112(5):1886-93.
2008: Leigh Ellis; Yan Pan; Gordon K Smyth; Daniel J George; Chris McCormack; Roxanne Williams-Truax; Monica Mita; Joachim Beck; Howard Burris; Gail Ryan; Peter Atadja; Dale Butterfoss; Margaret Dugan; Kenneth Culver; Ricky Johnstone; H Miles Prince
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4500-10.
2008: Yonghua Yang; Rekha Rao Manepalli; Jie Shen; Yun Tang; Warren C Fiskus; John Nechtman; Peter Atadja; Kapil N Bhalla
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.
Cancer research 2008;68(12):4833-42.
2008: Hendrik Verheul; Brenda Salumbides; Karen Van Erp; Hans-Joerg Hammers; Zheng (David) Qian; Tolib B Sanni; Peter Atadja; Roberto Pili
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3589-97.
2008: Chunrong Yu; Bret B Friday; Lin Yang; Peter Atadja; Dennis Wigle; Jann N. Sarkaria; Alex A. Adjei
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Neuro-oncology 2008;10(3):309-19.
2008: Elke De Bruyne; Tomas Bos; Kewal Asosingh; Isabelle Vande Broek; Eline Menu; Els Van Valckenborgh; Peter Atadja; Valérie Coiteux; Xavier Leleu; Kris Thielemans; Ben Van Camp; Karin Vanderkerken; Ivan Van Riet
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):2918-26.
2008: Anna Scuto; Mark Kirschbaum; Claudia Kowolik; Leo Kretzner; Agnes Juhasz; Peter Atadja; Vinod Pullarkat; Ravi Bhatia; Stephen Forman; Yun Yen; Richard Jove
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Blood 2008;111(10):5093-100.
2008: Qun Zhou; Agoston T Agoston; Peter Atadja; William G Nelson; Nancy E Davidson
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.
Molecular cancer research : MCR 2008;6(5):873-83.
2008: Yuen-Li Chung; Helen Troy; Rebecca Kristeleit; Wynne Aherne; Laura E Jackson; Peter Atadja; John R Griffiths; Ian R Judson; Paul Workman; Martin Leach; Mounia Beloueche-Babari
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Neoplasia (New York, N.Y.) 2008;10(4):303-13.
2007: Arthur Edwards; Jiannong Li; Peter Atadja; Kapil N Bhalla; Eric Haura
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Molecular cancer therapeutics 2007;6(9):2515-24.
2007: Warren C Fiskus; Yuan Ren; Alex Mohapatra; Purva Bali; Aditya Mandawat; Rekha Rao Manepalli; Bryan Herger; Yonghua Yang; Peter Atadja; Jie Wu; Kapil N Bhalla
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4882-90.
2007: Chunrong Yu; Bret B Friday; Jin-Ping Lai; Andrea McCollum; Peter Atadja; Lewis Roberts; Alex A. Adjei
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1140-8.
2007: Yukihiko Kato; Brenda Salumbides; Xiao-Fei Wang; Zheng (David) Qian; Simon Williams; Yongfeng Wei; Tolib B Sanni; Peter Atadja; Roberto Pili
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Molecular cancer therapeutics 2007;6(1):70-81.
2007: Qun Zhou; Peter Atadja; Nancy E Davidson
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
Cancer biology & therapy 2007;6(1):64-9.
2006: Warren C Fiskus; Michael Pranpat; Maria Balasis; Bryan Herger; Rekha Rao Manepalli; Arul M Chinnaiyan; Peter Atadja; Kapil N Bhalla
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Molecular cancer therapeutics 2006;5(12):3096-104.
2006: Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
2006: Zheng (David) Qian; Sushant Kachhap; Spencer J Collis; Hendrik Verheul; Michael A Carducci; Peter Atadja; Roberto Pili
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
Cancer research 2006;66(17):8814-21.
2006: Julius Leyton; John P Alao; Marco Da Costa; Alexandra V Stavropoulou; John R Latigo; Meg Perumal; Radhakrishna Pillai; Qimin He; Peter Atadja; Eric W-F Lam; Paul Workman; David M Vigushin; Eric O Aboagye
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Cancer research 2006;66(15):7621-9.
2006: Warren C Fiskus; Michael Pranpat; Purva Bali; Maria Balasis; Sandhya Kumaraswamy; Sandhya Boyapalle; Kathy Rocha; Jie Wu; Francis Giles; Paul W Manley; Peter Atadja; Kapil N Bhalla
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Blood 2006;108(2):645-52.
2006: Patricia Maiso; Xonia Carvajal-Vergara; Enrique M Ocio; Ricardo López-Pérez; Gema Mateo; Norma C Gutiérrez; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Cancer research 2006;66(11):5781-9.
2006: Zheng (David) Qian; Yukihiko Kato; Shabana Shabbeer; Yongfeng Wei; Hendrik Verheul; Brenda Salumbides; Tolib B Sanni; Peter Atadja; Roberto Pili
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):634-42.
2006: Roberto R Rosato; Sonia C Maggio; Jorge A Almenara; Shawn G Payne; Peter Atadja; Sarah Spiegel; Paul Dent; Steven Grant
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Molecular pharmacology 2006;69(1):216-25.
2005: Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Peter Atadja; Ruth Craig; Julie Vrana; Paul Dent; Steven Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Molecular cancer therapeutics 2005;4(11):1772-85.
2005: Liwei Chen; Songshu Meng; Hai Wang; Purva Bali; Wenlong Bai; Benyi Li; Peter Atadja; Kapil N Bhalla; Jie Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Molecular cancer therapeutics 2005;4(9):1311-9.
2005: Purva Bali; Michael Pranpat; James E Bradner; Maria Balasis; Warren C Fiskus; Fei Guo; Kathy Rocha; Sandhya Kumaraswamy; Sandhya Boyapalle; Peter Atadja; Edward Seto; Kapil N Bhalla
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
The Journal of biological chemistry 2005;280(29):26729-34.
2005: Prince George; Purva Bali; Srinivas Annavarapu; Anna Scuto; Warren C Fiskus; Fei Guo; Celia Sigua; Gautam Sondarva; Lynn Moscinski; Peter Atadja; Kapil N Bhalla
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Blood 2005;105(4):1768-76.
2004: Ellen Weisberg; Laurence Catley; J Kujawa; Peter Atadja; Stacy W Remiszewski; P Fuerst; C Cavazza; Kenneth C Anderson; James D Griffin
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Leukemia 2004;18(12):1951-63.
2004: Zheng (David) Qian; Xiaofei Wang; Sushant Kachhap; Yukihiko Kato; Yongfeng Wei; Lu Zhang; Peter Atadja; Roberto Pili
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Cancer research 2004;64(18):6626-34.
2004: Purva Bali; Prince George; Pamela Cohen; Jianguo Tao; Fei Guo; Celia Sigua; Anasuya Vishvanath; Anna Scuto; Srinivas Annavarapu; Warren C Fiskus; Lynn Moscinski; Peter Atadja; Kapil N Bhalla
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4991-7.
2004: Angela Brieger; Simone Boehrer; Simone Schaaf; Daniel Nowak; Martin Ruthardt; Soo-Zin Kim; Peter Atadja; Dieter Hoelzer; Paris S Mitrou; Eckhart Weidmann; Kai Uwe Chow
In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Biochemical pharmacology 2004;68(1):85-93.
2004: Annette Romanski; Biserka Bacic; Gesine Bug; Heike Pfeifer; Hilal Gul; Stacy W Remiszewski; Dieter Hoelzer; Peter Atadja; Martin Ruthardt; Oliver G Ottmann
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Haematologica 2004;89(4):419-26.
2004: Fei Guo; Celia Sigua; Jianguo Tao; Purva Bali; Prince George; Yunqing Li; Sylvie Wittmann; Lynn Moscinski; Peter Atadja; Kapil N Bhalla
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Cancer research 2004;64(7):2580-9.
2004: Peter Atadja; Lin Gao; Paul Kwon; Nancy Trogani; Heather Walker; Meier Hsu; Lakshmi Yeleswarapu; Nagarajan Chandramouli; Larry Perez; Richard Versace; Arthur Wu; Lidia C Sambucetti; Peter Lassota; Dalia Cohen; Kenneth W Bair; Alexander Wood; Stacy W Remiszewski
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Cancer research 2004;64(2):689-95.
2004: Peter Atadja; Meier Hsu; Paul Kwon; Nancy Trogani; Kapil N Bhalla; Stacy W Remiszewski
Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
Novartis Foundation symposium 2004;259():249-66; discussion 266-8, 285-8.
2003: Lianne Fuino; Purva Bali; Sylvie Wittmann; Sreenivasa Donapaty; Fei Guo; Hirohito Yamaguchi; Hong-Gang Wang; Peter Atadja; Kapil N Bhalla
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Molecular cancer therapeutics 2003;2(10):971-84.
2003: Laurence Catley; Ellen Weisberg; Yu-Tzu Tai; Peter Atadja; Stacy W Remiszewski; Teru Hideshima; Nicholas Mitsiades; Reshma Shringarpure; Richard LeBlanc; Dharminder Chauhan; Nikhil C Munshi; Robert Schlossman; Paul Richardson; James Griffin; Kenneth C Anderson
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
2003: Ramadevi Nimmanapalli; Lianne Fuino; Purva Bali; Maura Gasparetto; Michele Glozak; Jianguo Tao; Lynn Moscinski; Clayton Smith; Jie Wu; Richard Jove; Peter Atadja; Kapil N Bhalla
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Cancer research 2003;63(16):5126-35.
2002: Lin Gao; Maria A Cueto; Fred Asselbergs; Peter Atadja
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
The Journal of biological chemistry 2002;277(28):25748-55.
2002: Denise D Fischer; Richard Cai; Umesh Bhatia; Fred Asselbergs; Chuanzheng Song; Robert Terry; Nancy Trogani; Roland Widmer; Peter Atadja; Dalia Cohen
Isolation and characterization of a novel class II histone deacetylase, HDAC10.
The Journal of biological chemistry 2002;277(8):6656-66.
2002: Stacy W Remiszewski; Lidia C Sambucetti; Peter Atadja; Kenneth W Bair; Wendy D Cornell; Michael A Green; Kobporn Lulu Howell; Manfred Jung; Paul Kwon; Nancy Trogani; Heather Walker
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Journal of medicinal chemistry 2002;45(4):753-7.
2002: Peter Atadja; Yan Yan-Neale; Harry Towbin; Frank Buxton; Dalia Cohen
Gene expression profiling of epothilone A-resistant cells.
Novartis Foundation symposium 2002;243():119-32; discussion 132-6, 180-5.